During the past decade, Hôpital Ambroise Paré conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Ambroise Paré" #1 sponsor was "AB Science" with 2 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 2 trials sponsored, "Fédération Française de Pneumologie" with 2 trials sponsored and "Hospira, now a wholly owned subsidiary of Pfizer" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Ambroise Paré" #1 collaborator was "Federation of Medical Specialties" with 2 trials as a collaborator, "Baxter Healthcare Corporation" with 1 trials as a collaborator and "Société Française d'Anesthésie et de Réanimation" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Ambroise Paré" are "Colorectal Cancer" (2 trials), "Pulmonary Disease, Chronic Obstructive" (2 trials), "Acute Circulatory Failure" (1 trials), "Acute Renal Failure" (1 trials) and "Acute Respiratory Distress Syndrome" (1 trials). Many other conditions were trialed in "Hôpital Ambroise Paré" in a lesser frequency.

Most popular intervention types in "Hôpital Ambroise Paré" are "Drug" (9 trials), "Device" (6 trials), "Biological" (2 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Masitinib" (2 trials), "bevacizumab" (2 trials), "fluorouracil" (2 trials) and "irinotecan hydrochloride" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Ambroise Paré" are 18 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hôpital Ambroise Paré". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Hôpital Ambroise Paré, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Ambroise Paré, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".